Cathy Burgess and Natalie Clayton are quoted on the backlogs of onsite facility inspections by the U.S. Food and Drug Administration and how the delays put generic drug applications at risk.
In the News
April 9, 2021
Inside Health Policy, Inside Drug Pricing | FDA: Inspection Lag Puts Generic Drug Exclusivity at Risk
Media Contact